Insider Trading Activity Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) – Director Sold 3,500 shares of Stock

ME Staff
-
0

Insider Trading Activity For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Lewis Clayton Jr. Cantley , Director of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) reportedly Sold 3,500 shares of the company’s stock at an average price of 56.14 for a total transaction amount of $196,490.00 SEC Form

Insider Trading History For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

  • On 7/29/2013 Celgene European Investment Co, Major Shareholder, bought 708,333 with an average share price of $18.00 per share and the total transaction amounting to $12,749,994.00.View SEC Filing
  • On 1/21/2014 Glenn Goddard, SVP, sold 10,000 with an average share price of $34.71 per share and the total transaction amounting to $347,100.00.View SEC Filing
  • On 1/27/2014 Glenn Goddard, SVP, sold 7,000 with an average share price of $26.29 per share and the total transaction amounting to $184,030.00.View SEC Filing
  • On 2/10/2014 Glenn Goddard, SVP, sold 6,000 with an average share price of $30.44 per share and the total transaction amounting to $182,640.00.View SEC Filing
  • On 3/3/2014 Scott Biller, Insider, sold 6,000 with an average share price of $29.85 per share and the total transaction amounting to $179,100.00.View SEC Filing
  • On 3/3/2014 John Duncan Higgons, COO, sold 8,000 with an average share price of $29.85 per share and the total transaction amounting to $238,800.00.View SEC Filing
  • On 3/7/2014 John Duncan Higgons, COO, sold 14,646 with an average share price of $41.41 per share and the total transaction amounting to $606,490.86.View SEC Filing

    • Analyst Ratings For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
    These are 4 Hold Ratings, 7 Buy Ratings .
    The current consensus rating for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) is Buy (Score: 2.64) with a consensus target price of $62.88 , a potential (9.98% upside)

    Analyst Ratings History For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

    • On 7/22/2015 Northland Securities Initiated Coverage of rating Outperform with a price target of $132.00
    • On 11/9/2015 Roth Capital Lower Price Target of rating Neutral with a price target of $114.00 to $75.00
    • On 5/18/2016 SunTrust Banks, Inc. Boost Price Target of rating Buy with a price target of $57.00 to $65.00
    • On 6/13/2016 J P Morgan Chase & Co Upgraded rating Neutral to Overweight with a price target of $50.00 to $62.00
    • On 8/10/2016 Goldman Sachs Group, Inc. (The) Reiterated Rating Neutral with a price target of $46.00
    • On 8/19/2016 BTIG Research Initiated Coverage of rating Neutral
    • On 12/16/2016 Needham & Company LLC Reiterated Rating Buy with a price target of $60.00 to $54.00

    Recent Trading Activity for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)
    Shares of Agios Pharmaceuticals, Inc. closed the previous trading session at 57.17 down -0.06 -0.10% with 345,338 shares trading hands.